Loren Data's SAM Daily™

FBO DAILY ISSUE OF FEBRUARY 13, 2004 FBO #0808
SOLICITATION NOTICE

B -- Animal Care and Maintenance, Breeding and Molecular Testing and Expansion of the MTAG Transgenic Mouse Model Colony of Mammory Carcinoma

Notice Date

2/11/2004
 

Notice Type

Solicitation Notice
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
 

ZIP Code

20852
 

Solicitation Number

NCI-40035-NG
 

Response Due

2/26/2004
 

Archive Date

3/12/2004
 

Point of Contact

Malinda Holdcraft, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Caren Rasmussen, Lead Contract Specialist, Phone (301) 402-4509, Fax (301) 402-4513,
 

E-Mail Address

holdcram@exchange.nih.gov, cr214i@nih.gov
 

Description

The National Institutes of Health (NIH), National Cancer Institute (NCI), Laboratory of Tumor Immunology & Biology (LTIB) plans to procure on a sole source basis with Biocon, Inc., 15801 Crabbs Branch Way, Rockville, Maryland 20855, services for animal care and maintenance, breeding, molecular testing and expansion of the MTAG Transgenic Mouse Model Colony of Mammary Carcinoma. The supplies and services herein are being procured in accordance with the simplified acquisition procedures authorized by FAR Part 13. The North American Industry Classification System code is 112990 and the business size standard is $0.75M. The Laboratory of Tumor Immunology at the National Cancer Institute, NIH has long been involved in the development and analysis of immunotherapy strategies against solid tumors, including recombinant viral-based vaccines and adoptive T cell transfer. The ongoing evaluation of these strategies requires the production of more relevant preclinical animal models. The model under investigation has a number of important characteristics that support that goal. Biocon has provided animal care and maintenance for approximately 200 mice per month and the necessary breeding colonies. Contractor Requirements: Contractor shall be responsible for: (1) the expansion and molecular testing of the colony for the identification of both transgene-positive and transgene-negative female mice; (2) monitoring primary tumor growth over time in specified experiments; (3) administering biologics and other reagents or compounds in anticancer therapy protocols; and (4) drawing blood for serum and CBC/differential determinations as potential diagnostic or prognostic markers of disease progression and/or regression. It is also important to point out that transgene-negative female mice will be retained and used as age-matched controls where requested. Period of Performance: One year from date of award. This requirement will be processed as an Indefinite-Delivery type order. This procurement represents a continuation of work done through a prior contract (N02RC27014A), under which Laboratory of Tumor Immunology & Biology (LTIB) has been receiving professional services from Biocon for this particular mouse colony. Biocon, Inc. is the only source known to the NCI that can provide female hemizygous mice that contain molecular characteristics that are required for continuity of experiments in progress and offspring. The purpose of this acquisition with Biocon is to maintain and expand the transgenic breeding colony to investigate mechanistic questions in both tumor progression and antitumor therapy. Because the female transgenic mouse of interest will be hemizygous, it will be necessary for Biocon to screen the offspring via polymerase chain reaction (PCR) to identify the appropriate transgene-positive mice. It is imperative to future research data and studies to obtain and continue current experiment in progress. Failure to do so could invalidate the cornerstone of these important research projects, i.e., the accurate, timely and reliable assignment of transgenic mice for experimental studies focused on the development and analysis of immune-based therapeutic approaches to potentially intervene with malignant progression. This is not a request for competitive quotation. However, if any interested party believes it can perform the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other furnished information must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform this requirement. Capability statements must be received in the contracting office by 1:00 PM EST, February 26, 2004. If you have any questions they must be submitted in writing to Malinda Holdcraft, Purchasing Agent, at holdcram@exchange.nih.gov or by fax 301-402-4513. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Solicitation number must be cited on all correspondence, NCI-40035-NG.
 

Place of Performance

Address: NIH/NCI

Zip Code: 20892

Country: USA
 

Record

SN00520402-W 20040213/040211212045 (fbodaily.com)
 

Source

FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |